🚀 VC round data is live in beta, check it out!
Tempo Scan Pacific Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tempo Scan Pacific and similar public comparables like Crescent Biopharma, Eikon Therapeutics, Ocugen, Guizhou Sanli and more.
Tempo Scan Pacific Overview
About Tempo Scan Pacific
PT Tempo Scan Pacific Tbk operates in the pharmaceutical business in Indonesia. It is engaged in the production of tablet/caplets, effervescent powders, liquid/syrup, cream and ointment, and capsule dosage forms, and markets body care products. It operates through the following segments: The Pharmaceuticals segment, the Consumer Products and Cosmetics segment, and the Distribution Services segment. The company caters to both Indonesian and international markets.
Founded
1970
HQ
Employees
4.5K
Website
Financials (FY)
EV
$431M
Tempo Scan Pacific Financials
Tempo Scan Pacific reported last fiscal year revenue of $818M and EBITDA of $122M.
In the same fiscal year, Tempo Scan Pacific generated $311M in gross profit, $122M in EBITDA, and $82M in net income.
Tempo Scan Pacific P&L
In the most recent fiscal year, Tempo Scan Pacific reported revenue of $818M and EBITDA of $122M.
Tempo Scan Pacific expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $818M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $311M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 38% | XXX | XXX | XXX |
| EBITDA | — | XXX | $122M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Profit | — | XXX | $82M | XXX | XXX | XXX |
| Net Margin | — | XXX | 10% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tempo Scan Pacific Stock Performance
Tempo Scan Pacific has current market cap of $645M, and enterprise value of $431M.
Market Cap Evolution
Tempo Scan Pacific's stock price is $0.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $431M | $645M | 0.5% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTempo Scan Pacific Valuation Multiples
Tempo Scan Pacific trades at 0.5x EV/Revenue multiple, and 3.5x EV/EBITDA.
Tempo Scan Pacific Financial Valuation Multiples
As of April 18, 2026, Tempo Scan Pacific has market cap of $645M and EV of $431M.
Equity research analysts estimate Tempo Scan Pacific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tempo Scan Pacific has a P/E ratio of 7.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $645M | XXX | $645M | XXX | XXX | XXX |
| EV (current) | $431M | XXX | $431M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 4.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.4x | XXX | XXX | XXX |
| P/E | — | XXX | 7.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 76.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tempo Scan Pacific Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tempo Scan Pacific Margins & Growth Rates
Tempo Scan Pacific's revenue in the last fiscal year grew by 3%.
Tempo Scan Pacific's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Tempo Scan Pacific Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (10%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tempo Scan Pacific Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| Crescent Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eikon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocugen | XXX | XXX | XXX | XXX | XXX | XXX |
| Guizhou Sanli | XXX | XXX | XXX | XXX | XXX | XXX |
| Forte Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tempo Scan Pacific M&A Activity
Tempo Scan Pacific acquired XXX companies to date.
Last acquisition by Tempo Scan Pacific was on XXXXXXXX, XXXXX. Tempo Scan Pacific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tempo Scan Pacific
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTempo Scan Pacific Investment Activity
Tempo Scan Pacific invested in XXX companies to date.
Tempo Scan Pacific made its latest investment on XXXXXXXX, XXXXX. Tempo Scan Pacific invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tempo Scan Pacific
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tempo Scan Pacific
| When was Tempo Scan Pacific founded? | Tempo Scan Pacific was founded in 1970. |
| Where is Tempo Scan Pacific headquartered? | Tempo Scan Pacific is headquartered in Indonesia. |
| How many employees does Tempo Scan Pacific have? | As of today, Tempo Scan Pacific has over 4K employees. |
| Is Tempo Scan Pacific publicly listed? | Yes, Tempo Scan Pacific is a public company listed on Indonesia Stock Exchange. |
| What is the stock symbol of Tempo Scan Pacific? | Tempo Scan Pacific trades under TSPC ticker. |
| When did Tempo Scan Pacific go public? | Tempo Scan Pacific went public in 1994. |
| Who are competitors of Tempo Scan Pacific? | Tempo Scan Pacific main competitors are Crescent Biopharma, Eikon Therapeutics, Ocugen, Guizhou Sanli. |
| What is the current market cap of Tempo Scan Pacific? | Tempo Scan Pacific's current market cap is $645M. |
| What is the current revenue of Tempo Scan Pacific? | Tempo Scan Pacific's last fiscal year revenue is $818M. |
| What is the current EV/Revenue multiple of Tempo Scan Pacific? | Current revenue multiple of Tempo Scan Pacific is 0.5x. |
| Is Tempo Scan Pacific profitable? | No, Tempo Scan Pacific is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.